Printer Friendly

RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.

 RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO
 CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.
 COLLEGEVILLE, Pa., and MANNHEIM, Germany, Feb. 3 /PRNewswire/ -- Poulenc Rorer Inc., (NYSE: RPR) Boehringer Mannheim GmbH and Boehringer Mannheim Pharmaceuticals Corporation announced that they will co-develop and co-market Boehringer Mannheim's third generation bisphosphonate to be used in the treatment of bone metabolism disorders.
 Development will be targeted for cancer-related hypercalcemia and osteolysis (bone destruction), and simultaneously for osteoporosis. Approval of cancer-related indications will likely precede the osteoporosis indication. It will be jointly marketed world wide, although Japan is not part of the cooperative agreement.
 According to the agreement, Boehringer Mannheim will perform most of the pre-clinical development of the product as well as some clinical development. RPR will be responsible for the majority of clinical development for the
osteoporosis indication. The compound is currently in Phase I trials, and will enter Phase II in the first quarter of 1992.
 Terms of the agreement and projected sales of the product are not being disclosed.
 "RPR is pleased with this opportunity to bring additional depth to its global bone metabolism franchise, a key part of its R&D strategy, and to build a long-term relationship with Boehringer Mannheim," said Robert E. Cawthorn, Chairman and Chief Executive Officer, Rhone-Poulenc Rorer. "Their third generation bisphosphonate is one of the best compounds under development at this time. It will be an excellent addition to our product portfolio which includes Calsynar(R)/Calcimar(R) (salmon calcitonin), Bonefos(TM)/Clastoban(TM) (clodronate), and Menorest(TM) an estrogen patch pending approval."
 "Our collaboration with RPR is a key element in Boehringer Mannheim's U.S. pharmaceutical market entry," said Professor Ulrich Abshagen, Member of the Executive Board, Boehringer Mannheim GmbH. "RPR will be an excellent development and marketing partner on our breakthrough bisphosphonate compound. Their proven expertise in research of bone disease, and particularly osteoporosis, fits well with Boehringer Mannheim's own extensive activities in this field. Equally important to our decision is the complementary position of our sales forces in the European and U.S. markets."
 Rhone-Poulenc Rorer Inc. is a global pharmaceutical company dedicated to human health. It operates in the following major therapeutic areas: cardiovascular medicine; bone metabolism/ rheumatology; gastroenterology; central nervous system/analgesia; infectious diseases/AIDS; oncology; hypersensitivity; and plasma derivatives. RPR had 1991 sales of more than $3.8 billion and research and development spending of more than $440 million. The company operates in all major markets of the world.
 Boehringer Mannheim Pharmaceuticals Corporation has recently started commercial operations in the U.S. and develops and markets important new therapies for cardiovascular, metabolic and oncologic diseases. Boehringer Mannheim Pharmaceuticals is part of the worldwide operating Boehringer Mannheim Group, which specializes in diagnostics, orthopedics, pharmaceuticals and biochemicals.
 /delval/
 -0- 2/3/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or 215-454-3085, or investors relations, 215-454-3851/ CO: Rhone-Poulenc Rorer Inc.; Boehringer Mannheim Pharmaceuticals
 Corporation ST: Pennsylvania IN: MTC SU: JVN


JS -- PH002 -- 5938 02/03/92 06:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:491
Previous Article:RHONE-POULENC RORER REPORTS DOUBLING IN ANNUAL EARNINGS
Next Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR FEB. 3, 1992
Topics:


Related Articles
RHONE-POULENC RORER AGREES TO SELL $300 MILLION MARKET AUCTION PREFERRED SHARES
RHONE-POULENC RORER INCREASES QUARTERLY DIVIDEND
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
RHONE-POULENC RORER ISSUES ANNOUNCEMENT
RHONE-POULENC RORER AGAIN INCREASES QUARTERLY DIVIDEND
MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS
RHONE-POULENC RORER DEVELOPING A NEW GENERATION ANTI-MALARIA DRUG IN RESPONSE TO A SERIOUS PUBLIC HEALTH PROBLEM
RHONE-POULENC RORER AGAIN INCREASES QUARTERLY DIVIDEND

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters